BioSante Pharmaceuticals Announces FDA Filing and Review of NDA for Bio-E-Gel(R) (Business Wire via Yahoo! Finance)
LINCOLNSHIRE, Ill.----April 19, 2006--BioSante Pharmaceuticals, Inc. announced today that its new drug application for Bio-E-Gel , an innovative low-dose topical therapy for moderate-to-severe hot flashes in menopausal women, has been accepted for filing and review by the U.S.

BioSante Pharmaceuticals Announces FDA Filing and Review of NDA for Bio-E-Gel(R) (FinanzNachrichten)
BioSante Pharmaceuticals, Inc. (Amex:BPA) announced today that its new drug application (NDA) for Bio-E-Gel (transdermal estradiol gel), an innovative low-dose topical therapy for moderate-to-severe hot flashes in menopausal women, has been accepted for filing and review by the U.S. Food and Drug Administration (FDA).

St. Jude Medical Announces FDA Approval and U.S. Market Launch of the Merlin Patient Care System (Business Wire via Yahoo! Finance)
ST. PAUL, Minn.----April 17, 2006--St. Jude Medical, Inc. today announced U.S. Food and Drug Administration approval and market launch of its Merlin Patient Care System, a universal programmer for implantable cardioverter defibrillators and pacemakers.